177 related articles for article (PubMed ID: 35333596)
1. Development of a High-Throughput Screening Assay for Small-Molecule Inhibitors of Androgen Receptor Splice Variants.
Monaghan AE; Porter A; Hunter I; Morrison A; McElroy SP; McEwan IJ
Assay Drug Dev Technol; 2022 Apr; 20(3):111-124. PubMed ID: 35333596
[TBL] [Abstract][Full Text] [Related]
2. A sting in the tail: the N-terminal domain of the androgen receptor as a drug target.
Monaghan AE; McEwan IJ
Asian J Androl; 2016; 18(5):687-94. PubMed ID: 27212126
[TBL] [Abstract][Full Text] [Related]
3. Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain.
Banuelos CA; Tavakoli I; Tien AH; Caley DP; Mawji NR; Li Z; Wang J; Yang YC; Imamura Y; Yan L; Wen JG; Andersen RJ; Sadar MD
J Biol Chem; 2016 Oct; 291(42):22231-22243. PubMed ID: 27576691
[TBL] [Abstract][Full Text] [Related]
4. An androgen receptor N-terminal domain antagonist for treating prostate cancer.
Myung JK; Banuelos CA; Fernandez JG; Mawji NR; Wang J; Tien AH; Yang YC; Tavakoli I; Haile S; Watt K; McEwan IJ; Plymate S; Andersen RJ; Sadar MD
J Clin Invest; 2013 Jul; 123(7):2948-60. PubMed ID: 23722902
[TBL] [Abstract][Full Text] [Related]
5. Discovery of drugs that directly target the intrinsically disordered region of the androgen receptor.
Sadar MD
Expert Opin Drug Discov; 2020 May; 15(5):551-560. PubMed ID: 32100577
[No Abstract] [Full Text] [Related]
6. Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC.
Ji Y; Zhang R; Han X; Zhou J
Eur J Med Chem; 2023 Feb; 247():115077. PubMed ID: 36587421
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer.
Thiyagarajan T; Ponnusamy S; Hwang DJ; He Y; Asemota S; Young KL; Johnson DL; Bocharova V; Zhou W; Jain AK; Petricoin EF; Yin Z; Pfeffer LM; Miller DD; Narayanan R
Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2211832120. PubMed ID: 36577061
[TBL] [Abstract][Full Text] [Related]
8. Characterization of niphatenones that inhibit androgen receptor N-terminal domain.
Banuelos CA; Lal A; Tien AH; Shah N; Yang YC; Mawji NR; Meimetis LG; Park J; Kunzhong J; Andersen RJ; Sadar MD
PLoS One; 2014; 9(9):e107991. PubMed ID: 25268119
[TBL] [Abstract][Full Text] [Related]
9. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.
Dalal K; Roshan-Moniri M; Sharma A; Li H; Ban F; Hessein M; Hsing M; Singh K; LeBlanc E; Dehm S; Tomlinson Guns ES; Cherkasov A; Rennie PS
J Biol Chem; 2014 Sep; 289(38):26417-26429. PubMed ID: 25086042
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.
Li D; Tian G; Wang J; Zhao LY; Co O; Underill ZC; Mymryk JS; Claessens F; Dehm SM; Daaka Y; Liao D
Prostate; 2018 Nov; 78(15):1140-1156. PubMed ID: 30009471
[TBL] [Abstract][Full Text] [Related]
11. Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor.
Radaeva M; Ban F; Zhang F; LeBlanc E; Lallous N; Rennie PS; Gleave ME; Cherkasov A
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33801338
[TBL] [Abstract][Full Text] [Related]
12. EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer.
Brand LJ; Olson ME; Ravindranathan P; Guo H; Kempema AM; Andrews TE; Chen X; Raj GV; Harki DA; Dehm SM
Oncotarget; 2015 Feb; 6(6):3811-24. PubMed ID: 25669987
[TBL] [Abstract][Full Text] [Related]
13. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
Watson PA; Chen YF; Balbas MD; Wongvipat J; Socci ND; Viale A; Kim K; Sawyers CL
Proc Natl Acad Sci U S A; 2010 Sep; 107(39):16759-65. PubMed ID: 20823238
[TBL] [Abstract][Full Text] [Related]
14. Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells.
Johnston PA; Nguyen MM; Dar JA; Ai J; Wang Y; Masoodi KZ; Shun T; Shinde S; Camarco DP; Hua Y; Huryn DM; Wilson GM; Lazo JS; Nelson JB; Wipf P; Wang Z
Assay Drug Dev Technol; 2016 May; 14(4):226-39. PubMed ID: 27187604
[TBL] [Abstract][Full Text] [Related]
15. Development of a Benzothiazole Scaffold-Based Androgen Receptor N-Terminal Inhibitor for Treating Androgen-Responsive Prostate Cancer.
Kuznik NC; Solozobova V; Jung N; Gräßle S; Lei Q; Lewandowski EM; Munuganti R; Zoubeidi A; Chen Y; Bräse S; Cato ACB
ACS Chem Biol; 2021 Nov; 16(11):2103-2108. PubMed ID: 34506104
[TBL] [Abstract][Full Text] [Related]
16. Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor.
Fancher AT; Hua Y; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2019; 17(8):364-386. PubMed ID: 31502857
[TBL] [Abstract][Full Text] [Related]
17. High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer.
Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2018; 16(6):297-319. PubMed ID: 30109944
[TBL] [Abstract][Full Text] [Related]
18. Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain.
Hua Y; Azeem W; Shen Y; Zhang S; Olsen JR; Øyan AM; Ke X; Zhang W; Kalland KH
Pharmacol Res Perspect; 2018 Dec; 6(6):e00437. PubMed ID: 30410767
[TBL] [Abstract][Full Text] [Related]
19. Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity.
Sadar MD
Cancer Res; 2011 Feb; 71(4):1208-13. PubMed ID: 21285252
[TBL] [Abstract][Full Text] [Related]
20. High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions.
Hua Y; Shun TY; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2014 Sep; 12(7):395-418. PubMed ID: 25181412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
